ReviewFrontiers in oncology2016
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Review in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors.BMC medicine · 2025Pooled it
- Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.Acta neuropathologica communications · 2018Trial
- 2240 nm NIR-IV Photodynamic Therapy Can Reverse Ineffective Anti-OX40 Cancer Immunotherapy to Become Effective.ACS nano · 2025Article
- Engineering adoptive cell therapy for solid tumors.Medical oncology (Northwood, London, England) · 2025Review
- Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.Clinical and experimental medicine · 2025Review
- From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events.Asia Pacific allergy · 2024Review
- The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8Nature communications · 2024Article
- Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.Frontiers in immunology · 2024Article
- Development of a CD8Heliyon · 2023Article
- Enhancedanti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody.Frontiers in immunology · 2023Article
- Advancements in Cancer Immunotherapies.Vaccines · 2022Review
- Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.eLife · 2022Article
- Structural Basis of a Novel Agonistic Anti-OX40 Antibody.Biomolecules · 2022Article
- Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors.Frontiers in oncology · 2022Review
- Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity.Frontiers in oncology · 2022Review
- Review
- Emerging Therapeutic Agents for Colorectal Cancer.Molecules (Basel, Switzerland) · 2021Review
- Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers.Scientific reports · 2021Article
- What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.Journal of experimental & clinical cancer research : CR · 2021Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In healthy individuals, immune-checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules to evade eradication by the immune system. Over the past years, immune-checkpoint blockade of cytotoxic T lymphocyte antigen-4 and programed death-1 emerged as promising strategies to activate antitumor cytotoxic T cell responses. Although complete regression and long-term survival is achieved in some patients, not all patients respond. This review describes promising, novel combination approaches involving immune-checkpoint blockade in the context of the cancer-immunity cycle, aimed at increasing response rates to the single treatments. Specifically, we discuss combinations that promote antigen release and presentation, that further amplify T cell activation, that inhibit trafficking of regulatory T cells or MSDCs, that stimulate intratumoral T cell infiltration, that increase cancer recognition by T cells, and that stimulate tumor killing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.